info@PremierEndpoint.com (914) 315-9334

Armune BioScience has developed the peer-reviewed and validated prostate-cancer-risk-assessment technology Apifiny®—a cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer. We are delighted present a follow up interview with David Esposito, President and Chief Executive Officer at Armune BioScience, Kalamazoo, Michigan. Our original interview with […]

Oncology

How biomarkers cost Bristol-Myers the lung cancer market http://www.biopharmadive.com/news/biomarkers-bristol-myers-opdivo-lost-lung-cancer/435891/ You may have seen the recent commercials for Merck’s immuno-oncology drug Keytruda (pembrolizumab), with the cancer patient talking about the biomarker test she took that determined she had high levels of PDL1, allowing her to receive Keytruda as a first line therapy for her lung cancer […]

Interview with David Esposito of Armune BioScience
October 20, 2016

This is the first post in an interview series with CEOs of small- to mid-cap companies, in which we ask them about products in development. Here we talk with David Esposito, President and Chief Executive Officer at Armune BioScience, Ann Arbor, Michigan. DAVID ESPOSITO: Armune BioScience is an early stage, medical diagnostics company started in […]